Pfizer delivered robust Q2 2025 results, reporting $14.7 billion in revenue (up 10% operationally) and $0.78 adjusted EPS. Key drivers included double-digit growth from Comirnaty, Paxlovid and Abrysvo. The company raised its full-year adjusted EPS guidance to $2.90–3.10 while reaffirming revenue outlook of $61.0–64.0 billion, underscoring strong commercial execution and cost-saving initiatives.
Allogene Therapeutics, a clinical-stage biotechnology company, has selected the standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study.
The U.S. FDA has declined to approve an expanded indication for Johnson & Johnson’s multiple myeloma therapy, Darzalex Faspro. The decision, delivered via a Complete Response Letter, was not based on the drug’s clinical efficacy but on unresolved issues at a third-party manufacturing facility.
AbbVie reports positive topline results from its Phase 3 UP-AA trial, showing upadacitinib (RINVOQ) significantly improved scalp hair coverage in patients with severe alopecia areata.
Eli Lilly and Company announced results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study, demonstrating that participants treated with Kisunla (donanemab-azbt) for early symptomatic Alzheimer’s disease showed a continued slowing of decline over three years.
AstraZeneca‘s supplemental biologics license application (sBLA) for Imfinzi (durvalumab) has been approved and given priority review in the U.S. FDAÂ for the treatment of patients with [Read More…]
One of the most intriguing and intricate organelles in eukaryotic cells is the endoplasmic reticulum (ER), which is essential for calcium homeostasis, lipid metabolism, and [Read More…]
Novo Nordisk reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a favorable opinion, suggesting that [Read More…]
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under accelerated review, recommending lenacapavir, the company’s [Read More…]
AstraZeneca announced that its novel nanobody, gefurulimab, has successfully met its primary and all secondary endpoints in the PREVAIL Phase III trial for adults with generalized myasthenia gravis (gMG). The results showed that the once-weekly, self-administered treatment delivered statistically significant and clinically meaningful improvements in daily living activities for patients with this rare autoimmune disease.
